Can't find what you're looking for?
View the sitemap of available pages on our website or conduct a keyword search here.
If you still can't find the information you require please contact us.
- Our Company
- Developing science
- Delivering therapies
- Clinical
- Newsroom
- Press Releases
- Placing
- Clinical Update
- Clinical Update
- Final Results
- Acquisition
- Clinical Update - Blautix Phase I
- Clinical Update - Thetanix Phase I
- Clinical Update - Blautix Phase I
- Acquisition
- Clinical Update - Thetanix Phase I Trial in Paediatric Crohn's
- Interim results for the period ended 30 June 2016
- Clinical Update - Blautix Phase I Trial in IBS
- 4D pharma presents data on asthma programme
- 4D pharma presents data on RA programme
- Clinical Update - MicroDx Platform
- Final Results
- Interim results
- 4D pharma presents data on immuno-oncology programme
- Research Update on MicroRx Discovery Platform
- Clinical Trial Update - Regulatory Approval of Thetanix Paediatric Crohn's Trial
- Interim results for the period ended 30 June 2015
- Clinical Trial Update - Commenced Dosing of Phase I IBS Trial
- Placing
- Oncology candidate update
- Final Results
- Clinical Update - Blautix IND
- MRx0518 - Monotherapy trial approved
- 4D Presents Phase Ib Clinical Data on Blautix
- Research Collaboration
- Research Update
- Final Results
- Research Update
- Research Update
- Research Update
- Interim results for the period ended 30 June 2014
- Research Update
- Rosburix granted orphan drug designation
- Acquisition of The Microbiota Company Limited
- 4D Presents at IHMC 2018
- Placing
- 4D to present update on MRx0518 at upcoming meeting
- Clinical Collaboration Agreement
- MHRA and HPRA clear Blautix Phase II study
- Publication - microbiota as HDAC inhibitors
- 4D asthma publication
- 4D pharma Appoints Two Non-Executive Directors
- 4D to present Phase Ib results of Thetanix in paediatric Crohn's disease at ESPGHAN meeting
- Oncology Programmes Update
- 4D pharma plc Files SEC Forms in Process to Gain NASDAQ Listing Following Merger with Longevity, a Special Purpose Acquisition Company (SPAC)
- 4D pharma announces clinical trial collaboration with Merck KGaA and Pfizer to evaluate MRx0518 in combination with BAVENCIO® for the treatment of locally advanced or metastatic urothelial carcinoma
- 4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- 4D pharma Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022)
- Events
- Posters & Publications
- Video & Audio
- In The News
- Press Releases
- Investors
